PSMA PET Tracers With Fast Clearance for Prostate Tumor Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic tests for prostate cancer, such as the PSA test, are unreliable and invasive, and existing PET tracers for prostate cancer have low tumor-to-muscle ratios due to high blood activity and prolonged biologic half-life, limiting their effectiveness in detecting and grading prostate cancer.
Innovation Solution
Development of substrate-based PET imaging agents, including urea-based tracers with triazole side chains generated through click chemistry, which are strong inhibitors of PSMA and provide improved PK/clearance profiles, allowing for non-invasive diagnosis and grading of prostate cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mAb PET tracers are used for prostate cancer imaging, then they can target PSMA specifically, but they exhibit low clearance and high blood activity due to prolonged biologic half-life, resulting in low tumor-to-muscle ratios
Solution Approach 1:
The patent changes the molecular class from antibody to small molecule inhibitor, fundamentally altering pharmacokinetic parameters including half-life and clearance rate. The small molecule compounds exhibit rapid clearance and low blood activity while maintaining PSMA target specificity, directly resolving the contradiction between detection reliability and duration of action
Solution Approach 2:
The invention employs short-lived small molecule compounds that rapidly clear from the bloodstream, creating an optimal imaging window. These compounds provide sufficient signal for accurate tumor detection during the imaging period but are quickly eliminated, avoiding prolonged exposure and improving the tumor-to-muscle ratio
2Ease of operation
If PSA test is used for prostate cancer screening, then it is non-invasive and widely available, but it lacks reliability as PSA levels can be elevated for reasons other than prostate cancer and do not necessarily correlate with cancer presence
Solution Approach 1:
The patent introduces a new intermediary - a small molecule PSMA inhibitor radiotracer - that specifically binds to PSMA receptors on prostate cancer cells. This intermediary provides a direct visual link between the imaging system and cancer tissue, eliminating the indirect and non-specific nature of PSA blood level measurements while maintaining non-invasive screening capabilities through PET imaging
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new PET imaging agents offer enhanced tumor-to-muscle ratios and improved clearance profiles, enabling accurate detection and grading of prostate cancer without invasive procedures.
Implementation Method 1
positron emission tomography (PET)... radiopharmaceuticals used in PET... radiolabeled small molecule compounds
Data Source
AI summary
Compounds for targeting and agents for imaging, prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.